ESMO 2014

 
 
 

Plaza Mayor in Madrid; Photo by Don Paolo

The ESMO 2014 Congress took place September 26-30 in Madrid, Spain.

 

Cancer treatment during pregnancy can be safe

HT Staff Read Article
Published: 10/02/14

Two new studies suggest that children exposed to chemotherapy or radiotherapy in the womb can be spared negative long-term effects. At a median age of 6, most of the children exposed to radiation in utero had neuropsychological, behavioral, and general health outcomes that were within normal ranges. And children who were exposed to chemotherapy in the womb had normal mental and cardiac health at a median age of 2. [Read Article]

Combo shows potential as frontline therapy in PTCL

HT Staff Read Article
Published: 09/30/14

doc_and_patient_older_woman_Credit_NIH_230.jpg
Doctor and patient
Credit: NIH

Follow-up data from a phase 1 trial suggest brentuximab vedotin plus chemotherapy may be a feasible frontline option for patients with peripheral T-cell lymphoma (PTCL). At the ESMO 2014 Congress, investigators presented 2-year data from a trial of brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (BV+CHP) in patients newly diagnosed with PTCL. The estimated 2-year overall survival rate was 80% in these patients. [Read Article]

Drug can prevent chemo-induced nausea, vomiting

HT Staff Read Article
Published: 09/30/14

young_adult_pt_receiving_chemo_Credit_Rhoda_Baer_230.jpg
Patient receives chemotherapy
Credit: Rhoda Baer

A small molecule called rolapitant can prevent nausea and vomiting in patients receiving cisplatin-based chemotherapy, results of a phase 3 trial suggest. When given prior to chemotherapy, rolapitant induced a complete response in about 70% of patients. These patients had no emesis after chemotherapy and did not require any rescue medication. “This agent makes a significant difference in the way people tolerate their chemotherapy,” said Martin Chasen, MD. [Read Article]

Rivaroxaban rivals standard for VTE in cancer

HT Staff Read Article
Published: 09/29/14

prescriptions_Credit_CDC_230.jpg
Prescriptions
Credit: CDC

A pooled analysis of 2 studies suggests rivaroxaban prevents recurrent venous thromboembolism (VTE) in cancer patients as effectively as standard therapy, while conferring a lower risk of major bleeding. The analysis included data from the EINSTEIN-DVT and EINSTEIN-PE trials, which were funded by the companies developing rivaroxaban (Xarelto), Bayer HealthCare Pharmaceuticals and Janssen Research & Development, LLC. [Read Article]

FDA approves cancer drugs faster, study shows

HT Staff Read Article
Published: 09/29/14

chemo_drugs.jpg
Chemotherapeutic agents

The US Food and Drug Administration (FDA) tends to approve cancer drugs faster than Health Canada and the European Medicines Agency (EMA), according to a study presented at the ESMO 2014 Congress. On average, the FDA approved antineoplastic agents about 6 to 8 months faster than the EMA and Health Canada, researchers found. One of the drugs studied had been FDA-approved for more than 4.5 years before the EMA and Health Canada authorized its use.  [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}